| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/30/2014 | CN102083314B PARP inhibitor compounds, compositions and methods of use |
| 04/30/2014 | CN102050856B High-activity epirubicin derivative, preparation method thereof and application thereof |
| 04/30/2014 | CN101985471B Folate-IgG conjugate as well as preparation method and application thereof |
| 04/30/2014 | CN101904843B Use of compound for preparing bone destruction inhibitor |
| 04/30/2014 | CN101898962B Rhein crystal B-type solid matter, preparation method and use |
| 04/30/2014 | CN101875697B Design of novel anti-EGFR humanized antibody TGM10 and application thereof |
| 04/30/2014 | CN101724075B Remodeling and glycoconjugation of peptides |
| 04/30/2014 | CN101633655B Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| 04/30/2014 | CN101360826B Anti-alpha2 integrin antibodies and their uses |
| 04/29/2014 | US8710216 Organic compounds |
| 04/29/2014 | US8710202 Isolated nucleic acid molecule encoding an antibody that reduces GDF-8 activity |
| 04/29/2014 | US8710074 Dihydronaphthyridinyl(organo)methanone analogs as positive allosteric mGluR5 modulators |
| 04/29/2014 | US8710072 Morphinan compounds |
| 04/29/2014 | US8710058 Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
| 04/29/2014 | US8710048 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
| 04/29/2014 | US8710030 Phosphonate compounds |
| 04/29/2014 | US8710020 Clusterin antisense therapy for treatment of cancer |
| 04/29/2014 | US8710013 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
| 04/29/2014 | US8709998 Peptide vectors |
| 04/29/2014 | US8709995 Method for eliciting an immune response to human telomerase reverse transcriptase |
| 04/29/2014 | US8709812 Drug comprising as the active ingredient proliferative vector containing survivin promoter |
| 04/29/2014 | US8709443 Reovirus for the treatment of cellular proliferative disorders |
| 04/29/2014 | US8709442 Recombinant negative strand virus RNA expression systems and vaccines |
| 04/29/2014 | US8709430 Cancer treatment kits comprising therapeutic antibody conjugates that bind to aminophospholipids |
| 04/29/2014 | US8709425 Antibodies to non-functional P2X7 receptor |
| 04/29/2014 | US8709409 Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate |
| 04/29/2014 | US8709405 Cancer vaccines containing epitopes of oncofetal antigen |
| 04/29/2014 | US8709404 Immunotherapy in cancer treatment |
| 04/29/2014 | CA2753552C N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| 04/29/2014 | CA2669266C Pyridinone compounds |
| 04/29/2014 | CA2631931C Cancer therapies and pharmaceutical compositions used therein |
| 04/29/2014 | CA2570873C Pyrimidine urea derivatives as kinase inhibitors |
| 04/29/2014 | CA2516078C Catechol compositions and use thereof |
| 04/29/2014 | CA2408571C Mammalian receptor proteins; related reagents and methods |
| 04/29/2014 | CA2232048C Treatment or prevention of neoplastic and infectious diseases with heat shock/stress proteins |
| 04/24/2014 | WO2014063128A1 Cancer cell trap |
| 04/24/2014 | WO2014063068A1 Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| 04/24/2014 | WO2014063061A1 Hydrophobically tagged small molecules as inducers of protein degradation |
| 04/24/2014 | WO2014063054A1 Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| 04/24/2014 | WO2014063024A1 Preparation of and formulation comprising a mek inhibitor |
| 04/24/2014 | WO2014063012A1 Conjugated knottin mini-proteins containing non-natural amino acids |
| 04/24/2014 | WO2014062978A1 Molecular signatures of ovarian cancer |
| 04/24/2014 | WO2014062938A1 Rory modulators |
| 04/24/2014 | WO2014062878A2 Treatment of cancer with tor kinase inhibitors |
| 04/24/2014 | WO2014062778A1 Methods and compositions for the treatment of cancer |
| 04/24/2014 | WO2014062774A1 Pyrazolopyrimidine compounds for the treatment of cancer |
| 04/24/2014 | WO2014062732A1 Substituted benzene compounds |
| 04/24/2014 | WO2014062604A1 Compounds useful as inhibitors of atr kinase |
| 04/24/2014 | WO2014062566A1 Immunomodulation using spores and pollen grains |
| 04/24/2014 | WO2014062083A1 Pharmaceutical composition on the basis of phyto-nutrients with increased bioavailability, having anti-tumour activity, and method for producing said composition (alternatives) |
| 04/24/2014 | WO2014062004A1 Recombinant adenovirus comprising htert mrna targeting ribozyme and p53 gene |
| 04/24/2014 | WO2014061826A1 Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of cbp/catenin |
| 04/24/2014 | WO2014061821A1 Grb10 interacting gyf protein 2 modulator |
| 04/24/2014 | WO2014061693A1 Novel non-aromatic carbocyclic or non-aromatic heterocyclic derivative |
| 04/24/2014 | WO2014061419A1 Novel cancer marker and utilization thereof |
| 04/24/2014 | WO2014061277A1 Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| 04/24/2014 | WO2014060962A1 Pemetrexed dipotassium formulations |
| 04/24/2014 | WO2014060959A1 Crystalline pemetrexed dipotassium process |
| 04/24/2014 | WO2014060953A1 Process for preparing pemetrexed di potassium and its hydrates |
| 04/24/2014 | WO2014060770A1 Bicyclic heterocycle compounds and their uses in therapy |
| 04/24/2014 | WO2014060768A1 Bicyclic heterocycle compounds and their uses in therapy |
| 04/24/2014 | WO2014060767A1 Bicyclic heterocycle compounds and their uses in therapy |
| 04/24/2014 | WO2014060742A1 Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof |
| 04/24/2014 | WO2014060548A1 Anthocyanidin complex for the treatment of multiple myeloma |
| 04/24/2014 | WO2014060493A2 N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group |
| 04/24/2014 | WO2014060449A1 Multicomponent crystalline system comprising nilotinib and selected co-crystal formers |
| 04/24/2014 | WO2014060408A1 Anthracyline derivatives for treating tumor diseases |
| 04/24/2014 | WO2014060395A1 Serine/threonine kinase inhibitors |
| 04/24/2014 | WO2014060376A1 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
| 04/24/2014 | WO2014060371A1 Inhibitors of syk |
| 04/24/2014 | WO2014060366A1 N-substituted 3,4-bis (catechol) pyrrole compounds, and the preparation and use thereof in the treatment of cancer |
| 04/24/2014 | WO2014060364A1 Sulfestrol for treating cancer |
| 04/24/2014 | WO2014060358A1 Fosfestrol for use in curative or palliative treatment of cancer in female mammals |
| 04/24/2014 | WO2014060347A1 Fosfestrol for use in curative or palliative treatment of prostate cancer |
| 04/24/2014 | WO2014060210A1 Methods and compositions for the treatment of pancreatic cancer |
| 04/24/2014 | WO2014060113A1 Novel kinase inhibitors |
| 04/24/2014 | WO2014060112A1 Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| 04/24/2014 | WO2014059928A1 Anticancer and anti-obesity cyclic peptide agents |
| 04/24/2014 | WO2014059797A1 Use of ivermectin and derivatives thereof |
| 04/24/2014 | WO2014059740A1 Tetracyclic anthraquinone derivatives |
| 04/24/2014 | WO2014059649A1 Lycopene microcapsule preparation method |
| 04/24/2014 | WO2014059484A1 CANCER THERAPY USING miRNAs |
| 04/24/2014 | WO2014043403A4 Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
| 04/24/2014 | WO2013192550A3 Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| 04/24/2014 | WO2012044933A8 B and t lymphocyte attenuator marker for use in adoptive t-cell therapy |
| 04/24/2014 | DE202005022112U1 Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester Pharmaceutical controlled release compositions comprising a fumaric ester |
| 04/24/2014 | DE102012020542A1 Use of an active ingredient consisting of e.g. tocotrienols in the substantial absence of tocopherols, for the prevention or treatment of e.g. normal or pathological inflammatory diseases, pain, diseases of nervous system, and cancer |
| 04/23/2014 | EP2722386A1 Crushed cells and composition thereof |
| 04/23/2014 | EP2722343A1 ANTI-erbB3 ANTIBODY |
| 04/23/2014 | EP2722342A1 Methods and compositions for the treatment of pancreatic cancer |
| 04/23/2014 | EP2722334A1 Benzodiazepine bromodomain inhibitor |
| 04/23/2014 | EP2722332A1 Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof |
| 04/23/2014 | EP2722331A1 Crystal of pyrroloquinolinequinone disodium salt, and method for producing same |
| 04/23/2014 | EP2722057A2 A series of drugs using photofrin to catalyze decomposition of hydrogen peroxide |
| 04/23/2014 | EP2722049A1 A pharmaceutical composition for inhibiting recurrence, aggravation and metastasis of hepatocarcinoma |
| 04/23/2014 | EP2722046A1 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 1 |
| 04/23/2014 | EP2721071A1 Tem8 antibodies, conjugates thereof, and their use |
| 04/23/2014 | EP2721070A1 Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies |
| 04/23/2014 | EP2721035A1 Glioblastoma inhibiting compounds and their use |
| 04/23/2014 | EP2721033A1 Compounds, their pharmaceutical compositions and their uses as idh1 mutants inhibitors for treating cancers |